Dainippon Sumitomo, Glenmark neurology news

Dainippon's Sepracor Inc. unit granted Glenmark rights to launch its generic version of Lunesta eszopiclone on Nov. 30, 2013, or May 30, 2014, if Sepracor obtains pediatric exclusivity, to settle a 2009 suit filed in the U.S. District Court of New Jersey alleging that an ANDA filed by Glenmark for a generic version of Lunesta infringed Sepracor's U.S. Patent nos. 6,864,257; 6,319,926; 7,381,724 and 6,444,673. The ANDA contains a paragraph IV certification against the '257, '926, '673 and '724 patents, which expire Aug. 30, 2012, Jan. 16, 2012, Feb. 14, 2014 and Jan. 16, 2012, respectively. The agreement would also permit Glenmark to launch its generic product earlier under undisclosed circumstances. ...